Trials / Completed
CompletedNCT02357810
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 178 (actual)
- Sponsor
- Northwestern University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. To determine progression free rate at week 12 for patients with soft tissue sarcoma (STS) treated with pazopanib (pazopanib hydrochloride) plus oral topotecan (topotecan hydrochloride). SECONDARY OBJECTIVES: I. To determine the overall response rate for patients with STS treated with combination pazopanib and topotecan. II. To determine the clinical benefit rate (complete response \[CR\] + partial response \[PR\] + stable disease \[SD\]) for patients with STS treated with combination pazopanib and topotecan. III. To determine median progression-free rate (PFR) for patients with STS treated with combination pazopanib and topotecan. IV. To evaluate overall survival (OS) for patients with STS treated with combination pazopanib and topotecan. V. To assess safety and tolerability for patients treated with combination pazopanib and topotecan. VI. To estimate the PFR for patients with osteosarcoma treated with combination pazopanib and topotecan. VII. To estimate the PFR for patients with liposarcoma treated with combination pazopanib and topotecan. TERTIARY OBJECTIVES: I. To estimate the correlation of PFR and OS to levels of soluble vascular endothelial growth factor receptor 2 (sVEGFR2) and phosphatidylinositol-glycan biosynthesis class F (PIGF). OUTLINE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28 and topotecan hydrochloride PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity or until discontinuation per patient preference or physician recommendation. After completion of study treatment, patients are followed up every 6 months for 2 or 5 years.
Conditions
- Adult Liposarcoma
- Metastatic Liposarcoma
- Metastatic Osteosarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Liposarcoma
- Recurrent Osteosarcoma
- Stage IV Adult Soft Tissue Sarcoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pazopanib Hydrochloride | Given PO |
| DRUG | Oral Topotecan Hydrochloride | Given PO |
| OTHER | Laboratory Biomarker Analysis | Correlative studies |
Timeline
- Start date
- 2015-03-21
- Primary completion
- 2018-04-27
- Completion
- 2021-10-12
- First posted
- 2015-02-06
- Last updated
- 2022-06-07
- Results posted
- 2020-08-10
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02357810. Inclusion in this directory is not an endorsement.